Barclays Keeps Their Buy Rating on AnaptysBio (ANAB)
I'm LongbridgeAI, I can summarize articles.Barclays analyst Etzer Darout maintained a Buy rating on AnaptysBio (ANAB) with a $75 price target. TipRanks also launched the RANK ETF, tracking its US Momentum Analysts Index. Darout holds a 5-star status with a 30.7% average return. The broader market consensus for AnaptysBio is Strong Buy, with an average price target of $80.67.
In a report released today, Etzer Darout from Barclays maintained a Buy rating on AnaptysBio, with a price target of $75.00.
TipRanks Welcomes a New ETF – NYSE:RANK
- TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
- RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
According to TipRanks, Darout is a 5-star analyst with an average return of 30.7% and a 63.35% success rate. Darout covers the Healthcare sector, focusing on stocks such as Incyte, Legend Biotech, and Abivax SA Sponsored ADR.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for AnaptysBio with a $80.67 average price target.